MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • MDS Virtual Congress 2020

    Variants in the saposin D domain of prosaposin gene are linked to Parkinson’s disease

    Y. Oji, T. Hatano, S. Ueno, M. Funayama, K. Ishikawa, A. Okuzumi, S. Noda, S. Sato, W. Satake, T. Toda, Y. Li, T. Hino-Takai, S. Kakuta, T. Tsunemi, H. Yoshino, K. Nishioka, T. Hattori, Y. Mizutani, T. Mutoh, F. Yokochi, Y. Ichinose, K. Koh, K. Shindo, Y. Takiyama, T. Hamaguchi, M. Yamada, M. Farrer, Y. Uchiyama, W. Akamatsu, J. Matsuda, Y. Wu, N. Hattori (Tokyo, Japan)

    Objective: To investigate whether the variants of prosaposin can be linked to Parkinson's disease (PD) [1]. Background: Recent growing investigations have promoted the evidence of…
  • MDS Virtual Congress 2020

    Predicting Longitudinal Atrophy in Parkinson’s Disease using SIR model

    A. Abdelgawad, S. Rahayel, C. Tremblay, A. Vo, Y.Q Zheng, R. Markello, B. Misic, A. Dagher (Montreal, QC, Canada)

    Objective: To predict longitudinal brain changes in Parkinson's disease (PD) using an agent-based model. Background: Considerable evidence suggests that α-synuclein(α-syn) behaves in a prion-like fashion,…
  • MDS Virtual Congress 2020

    Morphological changes of retina in patients with Parkinson’s disease and the role of α-synuclein in retinal damage

    L. Man, Z. Wei (Chengdu, China)

    Objective: To analyze the characteristics of retinal structural changes in patients with PD by the noninvasive technology of OCT. Demonstrate the role of α-syn in pathological changes of…
  • MDS Virtual Congress 2020

    DJ1 and α-Synuclein as CSF biomarkers and gene polymorphisms: association with clinical parameters in Parkinson’s disease

    T. Syed, T. SD, R. Kandadai, V. Kutala, R. Borgohain (Hyderabad, India)

    Objective: To analyze the CSF α-Synuclein and DJ1 Biomarkers correlating with SNCA and DJ1 gene polymorphisms and clinical parameters in PD. Background: Currently there is…
  • MDS Virtual Congress 2020

    Genetic Profiling of Early Synucleinopathy in Rat Nigrostriatal Dopamine Neurons

    J. Patterson, C. Kemp, M. Duffy, J. Howe, C. Russell, A. Stoll, K. Miller, J. Beck, S. Counts, K. Steece-Collier, K. Luk, C. Sortwell (Grand Rapids, MI, USA)

    Objective: Identification of changes in gene expression in rat nigral neurons associated with early phases of synucleinopathy. Background: Early phases of synucleinopathies such as Parkinson’s…
  • MDS Virtual Congress 2020

    Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advanced Parkinson’s Disease

    K. Merchant, T. Simuni, B. Fiske, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff, C. Venuto (Chicago, IL, USA)

    Objective: To assess serum pharmacokinetics (PK) and cerebrospinal fluid (CSF) concentrations of nilotinib as well as CSF biomarker changes in NILO-PD study. Background: Several cell…
  • MDS Virtual Congress 2020

    Male-specific exacerbation of susceptibility to α-synuclein pre-formed fibrils by developmental dieldrin exposure in mice

    A. Gezer, J. Kochmanski, S. VanOeveren, A. Cole-Strauss, C. Kemp, J. Patterson, K. Miller, N. Kuhn, D. Herman, A. McIntire, J. Lipton, K. Luk, S. Fleming, C. Sortwell, A. Bernstein (Grand Rapids, MI, USA)

    Objective: To determine whether developmental exposure to dieldrin exacerbates susceptibility to α-synuclein (α-syn) preformed fibril (PFF)-induced synucleinopathy in adulthood. Background: Parkinson’s disease (PD) is characterized…
  • MDS Virtual Congress 2020

    Deposition of phosphorylated α-synuclein in the muscularis externa of the gastrointestinal tract in patients with prodromal Parkinson’s disease

    G. Beck, H. Mochizuki (Suita, Japan)

    Objective: In the present study, we investigated Lewy pathology in the enteric nervous system (ENS) of seven Parkinson’s disease (PD) patients who underwent a gastrectomy,…
  • MDS Virtual Congress 2020

    PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results

    G. Pagano, K. Taylor, J. Cabrera, M. Marchesi, W. Zago, R. Tripuraneni, A. Boulay, A. Vogt, F. Boess, T. Nikolcheva, H. Svoboda, M. Britschgi, F. Lipsmeier, M. Lindemann, S. Dziadek, J. Azulay, B. Mollenhauer, L. Manzanares, D. Russell, J. Boyd, A. Nicholas, M. Luquin, R. Hauser, T. Simuni, T. Gasser, W. Poewe, G. Kinney, R. Doody, P. Fontoura, D. Umbricht, A. Bonni (Basel, Switzerland)

    Objective: Evaluate efficacy and safety of prasinezumab following 52 weeks of treatment in participants with early Parkinson’s disease (PD). Background: Prasinezumab is a humanized monoclonal…
  • MDS Virtual Congress 2020

    Characterization of Lewy bodies-induced neurodegeneration and synucleopathy in wild-type mice

    E. Bezard, L. Zhang, X. Yu, X. Sun, Y. Zhang, G. Ran, S. Dovero, M. Persillet, P. Fernagut, B. Dehay, C. Qin (Beijing, China)

    Objective: To investigate the Lewy-body-induced degeneration and synucleopathy in wild-type mice while focusing upon origin of the Lewy bodies. Background: Neurodegenerative diseases, such as Parkinson’s…
  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley